Strategies towards more effective anticancer therapies: Targeting DNA damage response pathways

Expert Review of Clinical Pharmacology

Volumn 3, Issue 1, 2010, Pages 103-115

  Ashwell, Susan ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Checkpoint kinase; Chemotherapy; DNA damage response network; Poly(ADP ribose) polymerase; Potentiation; Radiotherapy

Indexed keywords

4 IODO 3 NITROBENZAMIDE; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; AZD 7762; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DOXORUBICIN; EXEL 3611; EXEL 844; GEMCITABINE; IC 83; IRINOTECAN; LY 2603618; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PEMETREXED; PF 00477736; PF 477736; SCH 900776; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; VELIPARIB; VRX 0466617; XL 844;

ACUTE LEUKEMIA; BRAIN METASTASIS; BRAIN RADIATION; BREAST CANCER; CANCER RADIOTHERAPY; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; COMBINATION CHEMOTHERAPY; DNA DAMAGE; DNA REPAIR; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; GLIOBLASTOMA; GLIOMA; HUMAN; LYMPHOMA; MELANOMA; METASTASIS; MONOTHERAPY; MYELODYSPLASTIC SYNDROME; NEOPLASM; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; RECOMMENDED DRUG DOSE; REVIEW; SOLID TUMOR; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

EID: 77949698506     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/ecp.09.51     Document Type: Review

References (22)

1. Longley DB, Johnston PG. Molecular mechanisms of drug resistance. J. Pathol. 205, 275-292 (2005).
2. Ame JC, Splenlehauer C, de Murcia G. The PARP superfamily. Bioessays 26, 882-893 (2004).
3. Malanga M, Althaus FR. The role of poly(ADP-ribose) in the DNA damage signaling network. Biochem. Cell Biol. 83, 354-364 (2005).
4. Memisologu A, Samson L. Base excision repair in yeast and mammals. Mutat. Res. 451, 39-51 (2000).
5. Virag L, Szabo C. The therapeutic potential of poly(ADP-ribose) inhibitors. Pharmacol. Rev. 54(3), 375-429 (2002).
6. Graziani G, Szabo C. Clinical perspectives of PARP inhibitors. Pharmacol. Res. 52(1), 109-118 (2005).
7. Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat. Rev. Drug Disc. 4(5) 421-440 (2005).
8. Horvath EM, Szabo C. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update. Drug News Perspect. 20(3), 171-181 (2007).
9. de Murcia JM, Niedergang C, Trucco C et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and cells. Proc. Natl Acad. Sci. USA 94, 7303-7307 (1997).
10. Bryant HE, Schultz N, Thomas HW et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-916 (2005).
11. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
12. Ashworth A. A synthetic lethal approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26, 3785-3790 (2008).
13. Lewis C, Low JA. Clinical poly(ADP-ribose)polymerase inhibitors for the treatment of cancer. Curr. Opin. Invest. Drugs 8(12), 1051-1056 (2006).
14. Plummer ER. Inhibition of poly(ADP-ribose polymerase in cancer. Curr. Opin. Pharmacol. 6, 362-368 (2006).
15. Ratnam K, Low JA. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin Cancer Res. 13(5), 1383-1388 (2007).
16. Jones C, Plummer ER. PARP inhibitors and cancer therapy - early results and potential applications. Br. J. Radiol. 81, S2-S5 (2008).
17. Tikhe JG, Webber SE, Hostomsky Z et al. Design, synthesis and evaluation of 3,4-dihydro-2H-[1,4]diazepino[6,7,1-hi] indol-1-ones as inhibitors of poly(ADP-ribose) polymerase. J. Med. Chem. 47(22), 5467-5481 (2004).
18. Thomas HD, Calabrese CR, Batey MA et al. Preclinical selection of a novel poly(ADP-ribose)polymerase inhibitor for clinical trial. Mol. Cancer Ther. 6(3), 945-956 (2007).
19. Calabrese CR, Almassy R, Barton S et al. Anticancer chemosensitization snd radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl Cancer Inst. 96, 56-67 (2005).
20. Daniel RA, Rozanska AL, Thomas HD et al. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin. Cancer Res. 15(4), 1241-1249 (2009).
21. Plummer ER, Middleton MR, Jones C et al. Temozolomide pharmacodynamics in patients with metastatic melanoma: DNA damage activity or repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin Cancer Res. 11(9), 3402-3409 (2005).
22. Plummer R, Middleton M, Wilson R et al. First in human Phase I trial of the PARP inhibitor AG-014699 with temozolomide (TMZ) in patients with advanced solid tumors. Am. Soc. Clin. Oncol. 23, (2005) (Abstract 3065).